English, Article edition: Cost-Effectiveness Comparison of Salmeterol/Fluticasone Propionate versus Montelukast in the Treatment of Adults with Persistent Asthma Ketan Sheth; Rohit Borker; Amanda Emmett; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119178
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost-Effectiveness Comparison of Salmeterol/​Fluticasone Propionate versus Montelukast in the Treatment of Adults with Persistent Asthma
Author
  • Ketan Sheth
  • Rohit Borker
  • Amanda Emmett
  • Kathleen Rickard
  • Paul Dorinsky
Physical Description
  • article
Notes
  • Objective: To compare the relative cost effectiveness of salmeterol (50mug)/​ fluticasone propionate (100mug) with that of oral montelukast (10mg) as initial maintenance therapy in patients with persistent asthma uncontrolled on short-acting beta2-agonist therapy alone. Study design: A cost-effectiveness analysis was performed based on effectiveness and resource utilisation data that was prospectively collected from a randomised, double-blind, double-dummy, 12-week trial. Patients and methods: Patients (>15 years of age) who had asthma for at least 6 months. Effectiveness measurements in this analysis included improvement in forced expiratory volume in 1 second (FEV1) and symptom-free days (SFDs). Cost of asthma drug treatment as well as costs related to an asthma exacerbation were used in the cost analysis. The study assumed a payer's perspective. All costs are in 2001 US dollars. Results: Of the 423 patients eligible for the study, 211 were randomised to salmeterol/​fluticasone propionate and 212 to montelukast. Treatment with salmeterol/​fluticasone propionate resulted in a significantly higher proportion of patients who achieved a 12% increase in FEV1 (successful treatment) [salmeterol/​fluticasone propionate: 71% vs montelukast: 39%; p < 0.001] and percentage of SFDs (salmeterol/​fluticasone propionate: 46.8% vs montelukast: 21.5%; p < 0.001) compared with montelukast. The mean daily costs per successfully treated patient were lower in the salmeterol/​fluticasone propionate group ($US5.03, 95% CI $US4.61 to $US5.50) compared with the montelukast group ($US8.25, 95% CI $US6.98 to $US9.93). Furthermore, per patient mean daily cost per SFD was lower with salmeterol/​fluticasone propionate ($US7.63, 95% CI $US6.90 to $US8.50) compared with montelukast ($US14.89, 95% CI $US12.36 to $US17.98). Incremental cost-effectiveness ratios (ICERs) showed that the additional costs to achieve these benefits with salmeterol/​fluticasone propionate were minimal. With regards to improvement in lung function, the ICER was $US1.33 (95% CI $US0.80 to $US2.02) and with regards to SFD, the ICER was $US1.69 (95% CI $US1.01 to $US2.48). Sensitivity analysis demonstrated the stability of the results over a range of assumptions. Conclusions: From a third-party payer perspective, this analysis shows that based on increased efficacy and only a slight increase in cost, twice-daily treatment with salmeterol/​fluticasone propionate is more cost effective than once-daily treatment with montelukast as initial maintenance therapy for persistent asthma. This finding complements the results of the clinical analyses indicating that treatment of both inflammation and bronchoconstriction with products such as salmeterol/​ fluticasone propionate may be more cost effective as initial maintenance asthma therapy than the use of leukotriene modifiers such as montelukast.
  • Asthma, Beta 2 adrenoceptor agonists, Cost effectiveness, Leukotriene D4 antagonists, Montelukast, Pharmacoeconomics, Salmeterol/​fluticasone propionate
  • RePEc:wkh:phecon:v:20:y:2002:i:13:p:909-918
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment